Product development issues for PEGylated proteins

Pharmaceutical Development and Technology

Volumn 16, Issue 5, 2011, Pages 423-440

  Payne, Robert W ^a   Murphy, Brian M ^a   Manning, Mark Cornell ^a  

^a Legacy BioDesign LLC   (United States)

Author keywords

Chemical modification; Development; Pegylation; Protein stability

Indexed keywords

ALBUMIN; ASPARAGINASE MACROGOL; BLOOD CLOTTING FACTOR 8; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ENDOSTATIN; GLUCAGON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE RELEASING FACTOR; HEMOGLOBIN; HIRUDIN; HUMAN GROWTH HORMONE; INSULIN; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OCTREOTIDE; PARATHYROID HORMONE; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PEGYLATED PROTEIN; PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STAPHYLOKINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URATE OXIDASE;

ANION EXCHANGE CHROMATOGRAPHY; BINDING SITE; CAPILLARY ELECTROPHORESIS; CIRCULAR DICHROISM; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PURITY; DRUG SOLUBILITY; DRUG SPECIFICITY; ENZYME IMMUNOASSAY; FREEZE DRYING; GEL PERMEATION CHROMATOGRAPHY; HYDROPHILIC INTERACTION CHROMATOGRAPHY; INFRARED SPECTROSCOPY; ION EXCHANGE CHROMATOGRAPHY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PEPTIDE MAPPING; PHASE SEPARATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; STOICHIOMETRY; SYSTEMATIC REVIEW; VISCOSITY;

CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; HUMANS; PEPTIDES; POLYETHYLENE GLYCOLS; PROTEIN STABILITY; PROTEINS;

EID: 80052908831     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.513990     Document Type: Review

References (245)

1. Reinders J, Sickmann A. Modifcomics: Posttranslational modifcations beyond protein phosphorylation and glycosylation. Biomolec Engineer 2007;24:169-177. (Pubitemid 46755013)
2. Sola RJ, Griebenow K. Efects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009;98:1223-1245.
3. Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363-380.
4. Hamidi M, Azadi A, Rafei P. Pharmacokinetic consequences of pegylation. Drug Deliv 2006;13:399-409. (Pubitemid 44470219)
5. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. PEGylated proteins: Evaluation of their safety in the absence of defnitive metabolism studies. Drug Metabol Disposit 2007;35:9-16. (Pubitemid 46036470)
6. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002;54: 531-545. (Pubitemid 34615547)
7. Harris JM, Martin NE, Modi M. Pegylation-a novel process for modifying pharmacokinetics. Clin Pharmacokin 2001;40: 539-551. (Pubitemid 32738660)
8. Fishburn CS. Te pharmacology or PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97: 4167-4183.
9. Jevsavar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113-128.
10. Bailon P, Won CY. PEG-modifed biopharmaceuticals. Expert Opin Drug Deliv 2009;6:1-16.
11. Veronese FM, Mero A. Te impact of PEGylation on biological therapies. Biodrugs 2008;22:315-329.
12. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-1458. (Pubitemid 41483874)
13. Veronese FM. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 2001;22:405-417. (Pubitemid 32007845)
14. Katre N V. Te conjugation of proteins with polyethylene-glycol and other polymers-altering properties of proteins to enhance their therapeutic potential. Adv Drug Deliv Rev 1993;10:91-114. (Pubitemid 23158693)
15. Delgado C, Francis GE, Fisher D. Te uses and properties of peg-linked proteins. Crit Rev Terapeut Drug Carrier Syst 1992;9:249-304.
16. Ryan SM, Mantovani G, Wang XX, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin Drug Deliv 2008;5:371-383. (Pubitemid 351721718)
17. Pasut G, Veronese FM. Pegylation for improving the efectiveness of therapeutic biomolecules. Drugs Today 2009;45:687-695.
18. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Deliv Rev 2009;61:1177-1188.
19. Pasut G, Sergi M, Veronese FM. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008;60:69-78. (Pubitemid 350181167)
20. Harris JM, Chess RB. Efect of pegylation on pharmaceuticals. Nature Rev: Drug Discov 2003;2:214-221.
21. Zapilsky S. Chemistry of polyethylene glycol conjugates with biologically active moleucles. Adv Drug Deliv Rev 1995;16:157-182.
22. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010;99:2557-2575.
23. Hamburger R, Azaz E, Donbrow M. Autoxidation of polyoxyethylenic nonionic surfactants and of polyethylene glycols. Pharmaceut Acta Helvet 1975;50:10-17.
24. Mcginity JW, Patel TR, Naqvi AH, Hill JA. Implications of peroxide formation in lotion and ointment dosage forms containing polyethylene glycols. Drug Develop Communic 1976;2:505-519.
25. Johnson DM, Taylor WF. Degradation of fenprostalene in polyethylene glycol-400 solution. J Pharm Sci 1984;73:1414-1417. (Pubitemid 14021896)
26. Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, Reed RA. Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci 2007;96:106-116. (Pubitemid 46087343)
27. Bindra DS, Williams TD, Stella VJ. Degradation of O-6-benzylguanine in aqueous polyethylene-glycol-400 (Peg-400) solutions-concerns with formaldehyde in Peg-400. Pharmaceut Res 1994;11:1060-1064. (Pubitemid 24227656)
28. Nassar MN, Nesarikar VN, Lozano R, Parker WL, Huang YD, Palaniswamy V, Xu WW, Khaselev N. Infuence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: Identifcation and control of the degradation product. Pharm Dev Technol 2004;9:189-195. (Pubitemid 38788646)
29. Ellis G. Degradation of crystalline polyethylene glycol 6000 and its efect on assays for macroprolactin and other analytes. Clin Biochem 2006;39:1035-1040. (Pubitemid 44444961)
30. Huang TH, Garceau ME, Gao P. Liquid chromatographic determination of residual hydrogen peroxide in pharmaceutical excipients using platinum and wired enzyme electrodes. J Pharmaceut Biomed Analysis 2003;31:1203-1210. (Pubitemid 36349737)
31. Ruiz L, Reyes N, Duany L, Franco A, Aroche K, Rando EH. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. Int J Pharm 2003;264:57-72. (Pubitemid 37297634)
32. Gitlin G, Tsarbopoulos A, Patel ST, Sydor W, Pramanik BN, Jacobs S, Westreich L, Mittelman S, Bausch JN. Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b. Pharmaceut Res 1996;13:762-769. (Pubitemid 26156227)
33. Puz MJ, Johnson BA, Murphy BJ. Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug. Pharm Dev Technol 2005;10:115-125. (Pubitemid 40315535)
34. Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Develop 2008;11:242-250. (Pubitemid 351281064)
35. Kawai F. Microbial degradation of polyethers. Appl Microbiol Biotechnol 2002;58:30-38. (Pubitemid 34143300)
36. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharmaceut Sci 2000;3:125-136.
37. Yamashita M, Tani A, Kawai F. A new ether-spitting enzyme found in Gram-positive polyethylene glycol 6000-utilizing bacterium, Pseudonocardia sp. strain K1. Appl Microbiol Biotechnol 2004;66:174-179. (Pubitemid 40064311)
38. Beranova M, Wasserbauer R, Vancurova D, Stifter M, Ocenaskova J, Mara M. Efect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. Biomaterials 1990;11:521-524. (Pubitemid 20329115)
39. Donbrow M, Azaz E, Pillersdorf A. Autoxidation of polysorbates. J Pharm Sci 1978;67:1676-1681. (Pubitemid 9086684)
40. Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 2002;91:2252-2264.
41. Kumar V, Kalonia DS. Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations. AAPS Pharmscitech 2006;7: article 62.
42. Seely JE, Buckel SD, Green PD, Richey CW. Making site-specifc PEGylation work. Biopharm Int 2005;18:30+.
43. Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. A branched monomethoxypoly(ethylene glycol) for protein modifcation. Bioconj Chem 1995;6:62-69.
44. Fee CJ, Van Alstine JA. PEG-proteins: Reaction engineering and separation issues. Chem Engineer Sci 2006;61:924-939.
45. Fee CJ. Size comparison between proteins PEGylated with branched and linear Poly(Ethylene glycol) molecules. Biotechnol Bioengineer 2007;98:725-731. (Pubitemid 350032676)
46. Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Progress Polymer Sci 2007;32:933-961. (Pubitemid 47198290)
47. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54:459-476. (Pubitemid 34615543)
48. Canalle LA, Lowik DWPM, van Hest JCM. Polypeptide-polymer bioconjugates. Chem Soc Rev 2010;39:329-353.
49. Herman S, Hooftman G, Schacht E. Poly(ethylene glycol) with reactive endgroups. 1. Modifcation of proteins. J Bioactive Compatible Polymers 1995;10:145-187.
50. Abuchowski A, Kazo GM, Verhoest CR, Vanes T, Kafkewitz D, Nucci ML, Viau AT, Davis FF. Cancer-therapy with chemically modifed enzymes.1. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7:175-186. (Pubitemid 14087243)
51. Harris JM, Kozlowski A. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functionalized derivatives thereof for biochemical applications. US Patent No. 5,572,662, 1997.
52. Abuchowski A, Vanes T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum-albumin by covalent attachment of polyethylene-glycol. J Biolog Chem 1977;252:3578-3581. (Pubitemid 8116087)
53. Abuchowski A, McCoy JR, Palczuk NC, Vanes T, Davis FF. Efect of covalent attachment of polyethylene-glycol on immunogenicity and circulating life of bovine liver catalase. J Biolog Chem 1977;252:3582-3586. (Pubitemid 8116088)
54. Elling L, Kula MR. Immunoafnity partitioning synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies. Biotechnol Appl Biochem 1991;13:354-362.
55. Greenwald RB, Martinez AJ. Cyclic imide thione activated polyalkylene oxides. 5,405,877, 1995.
56. Harris JM, Sedaghat-Herati MR. Preparation and use of polyethylene glycol propionaldehyde. US Patent No. 5,252,714, 1993.
57. Bentley MD, Harris JM. Poly(ethyelene glycol) aldehyde hydrates and related polymers and applications in modifying amines. US Patent No. 5,990,237, 1999.
58. Delgado C, Patel JN, Francis GE, Fisher D. Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride-characterization of the conjugate by partitioning in aqueous 2-phase systems. Biotechnol Appl Biochem 1990;12:119-128. (Pubitemid 20216086)
59. Zapilsky S. Active carbonates of polyalkylene oxides for modifcation of polypeptides. US Patent No. 5,122,614, 1992.
60. Veronese FM, Largajolli R, Boccu E, Benassi CA, Schiavon O. Surface modifcation of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modifcation of ribonuclease and superoxide dismutase. Appl Biochem Biotechnol 1985;11:141-152. (Pubitemid 15021951)
61. Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modifed gelatin nanoparticles for intracellular delivery. Pharmaceut Res 2002;19:1061-1067. (Pubitemid 34804251)
62. Lee BK, Kwon JS, Kim HJ, Yamamoto S, Lee EK. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specifc modifcation: Process performance, characterization, and in vitro bioactivity. Bioconjug Chem 2007;18:1728-1734. (Pubitemid 350219969)
63. Miron T, Wilchek M. A simplifed method for the preparation of succinimidyl carbonate polyethylene-glycol for coupling to proteins. Bioconjug Chem 1993;4:568-569.
64. Tan YY, Sun XH, Xu MX, An ZL, Tan XZ, Tan XY, Han QH, Miljkovic DA, Yang M, Hofman RM. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Express Purifcat 1998;12:45-52. (Pubitemid 28361968)
65. Davis FF, Van Es T, Palczuk NC. Non-immunogenic polypeptides. US Patent No. 4,179,337, 1979.
66. Zapilsky S, Meno-Rudolph S. Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates, in polyethylene glycol chemistry and biological applications. ACS Sympos Series 1997;680:318-341.
67. Greenwald RB, Pendri A, Blikal D. Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. J Organic Chem 1995;60:331-336.
68. Dolence EK, Hu C-Z, Tsang R, Sanders CG, Osaki S. Electrophilic polyethylene oxides for the modifcation of polysaccharides, polypeptides (proteins) and surfaces. US Patent No. 5.650,234, 1997.
69. Freitas DdS, Spencer PJ, Vassao RC, Abrahao-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm 2010;387:215-222.
70. Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasutt G. Site-specifc pegylation of G-CSF by reversible denaturation. Bioconj Chem 2007;18:1824-1830. (Pubitemid 350219980)
71. Morpurgo M, Veronese FM, Kachensky D, Harris JM. Preparation and characterization of poly(ethylene glycol) vinyl sulfone. Bioconj Chem 1996;7:363-368. (Pubitemid 126639671)
72. Woghiren C, Sharma B, Stein S. Protected thiol-polyethylene-glycol-a new activated polymer for reversible protein modifcation. Bioconj Chem 1993;4:314-318.
73. Goodson RJ, Katre N V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Bio-Technology 1990;8:343-346. (Pubitemid 20138305)
74. Manjula BN, Tsai AG, Intaglietta M, Tsai C-H, Ho C, Smith PK, Perumalsamy K, Kamika ND, Friedman JM, Acharya SA. Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: Infuence on hemoglobin structure and function. Protein J 2005;24:133-146. (Pubitemid 41159991)
75. Acharya SA, Freidman JM, Manjula BN, Intaglietta M, Tsai AG, Winslow RM, Malavalli A, Vandegrif KD, Smith PK. Enhanced molecular volume of conservatively pegylated Hb: (SP-PEG5K)6-HbA is non-hypertensive. Artif Cells, Blood Substit Biotechnol 2005;33:239-255. (Pubitemid 41190931)
76. Peleg-Shulmann T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shecter Y. Reversible PEGylation: A novel technology to release native interferon α2 over a long period of time. J Medicinal Chem 2004;47:4897-4904. (Pubitemid 39238265)
77. Shechter Y, Mironchik M, Saul A, Gershonov E, Precido-Patt L, Sasson K, Tsubery H, Mester B, Kapitovsky A, Rubinaut S, Vachutinski Y, Fridkin G, Fridkin M. New technologies to prolong life-time of peptide and protein drugs in vivo. Int J Peptide Res Terapeut 2006;12:105-117. (Pubitemid 46888441)
78. Garman AJ, Kalindjian SB. Te preparation and properties of novel reversible polymer-protein conjugates-2-omega-methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators. FEBS Lett 1987;223:361-365. (Pubitemid 17155969)
79. Roberts MJ, Harris JM. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efcacy. J Pharm Sci 1998;87:1440-1445.
80. Kirpotin D, Hong KL, Mullah N, Papahadjopoulos D, Zalipsky S. Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Letters 1996;388:115-118. (Pubitemid 26226342)
81. Greenwald RB, Choe YH, McGuire J, Conover CD. Efective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003;55:217-250. (Pubitemid 36135917)
82. Zhao H, Yang K, Martinez A, Basu A, Chintala R, Liu HC, Janjua A, Wang ML, Filpula D. Linear and branched bicin linkers for releasable PEGylation of macromolecules: Controlled release in vivo and in vitro from mono-and multi-PEGylated proteins. Bioconj Chem 2006;17:341-351.
83. Shechter Y, Mironchik M, Rubinaut S, Tsubery H, Sasson K, Marcus Y, Fridkin M. Reversible pegylation of insulin facilitates its prolonged action in vivo. Eur J Pharmaceut Biopharmaceut 2008;70:19-28.
84. Fipula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 2008;60:29-49. (Pubitemid 350181165)
85. Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S. Site-specifc PEGylation of protein disulfde bonds using a three-carbon bridge. Bioconj Chem 2007;18:61-76. (Pubitemid 46145995)
86. Shaunak S, Godwin A, Choi JW, Balan S, Pedone E, Vijayarangam D, Heidelberger S, Teo I, Zloh M, Brocchini S. Site-specifc PEGylation of native disulfde bonds in therapeutic proteins. Nature Chem Biol 2006;2:312-313. (Pubitemid 43787211)
87. Brocchini S, Godwin A, Balan S, Choi SW, Zloh M, Shaunak S. Disulfde bridge based PEGylation of proteins. Adv Drug Deliv Rev 2008;60:3-12. (Pubitemid 350181163)
88. Hershfeld MS, Chafee S, Korojohnson L, Mary A, Smith AA, Short SA. Use of site-directed mutagenesis to enhance the epitope-shielding efect of covalent modifcation of proteins with polyethylene-glycol. Proc Nat Acad Sci USA 1991;88:7185-7189. (Pubitemid 21915114)
89. He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosantin by site-directed pegylation. Life Sci 1995;65:355-368.
90. Lee S, McNemar C. Substantially pure histidine-linked protein polymer conjugates. US Patent No. 5,985,263, 1999.
91. Shozen N, Iijima I, Hohsaka T. Site-specifc incorporation of PEGylated amino acids into protein using non-natural amino acid mutagenesis. Bioorg Medicin Chem Lett 2009;19:4909-4911.
92. Deiters A, Schultz PG. In vivo incorporation of an alkyne into proteins in Escherichia coli. Bioorgan Medicin Chem Lett 2005;15:1521-1524. (Pubitemid 40269024)
93. Orsatti L, Veronese FM. A unusual coupling of poly(ethylene glycol) to tyrosine residues in epidermal growth factor. J Bioact Compat Polym 1999;14:429-436. (Pubitemid 29455897)
94. Gaertner H F, Puigserver AJ. Increased activity and stability of polyethylene glycol-modifed trypsin. Enzyme Microb Technol 1992;14:150-155.
95. Salmaso S, Semenzato A, Bersani S, Mastrotto F, Scomparin A, Caliceti P. Site-selective protein glycation and PEGylation. Eur Polymer J 2008;44:1378-1389.
96. Sato H, Ikeda M, Suzuki K, Hirayama K. Site-specifc modifcation of interleukin-2 by the combined use of genetic engineering techniques and transglutaminase. Biochemistry 1996;35:13072-13080. (Pubitemid 26349457)
97. Sato H. Enzymatic procedure for site-specifc pegylation of proteins. Adv Drug Deliv Rev 2002;54:487-504. (Pubitemid 34615545)
98. Fontana A, Spolaore B, Mero A, Veronese FM. Site-specifc modifcation and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 2008;60:13-28. (Pubitemid 350181164)
99. Maullu C, Raimondo D, Caboi F, Giogetti A, Sergi M, Valentini M, Tonon G, Tramonto A. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor. FEBS J 2009;276:6741-6750.
100. DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van Der Linden ECM, Bayer RJ, Tarp MA, Clausen H. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 2006;16:833-843. (Pubitemid 44390927)
101. Graham ML. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-1302. (Pubitemid 37464563)
102. Levy Y, Hershfeld MS, Fernandezmejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU. Adenosine-deaminase defciency with late onset of recurrent infections response to treatment with polyethylene-glycol modifed adenosine-deaminase. J Pediatrics 1988;113:312-317.
103. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54:547-570. (Pubitemid 34618512)
104. Veronese FM, Sacca B, de Laureto PP, Sergi M, Caliceti P, Schiavon O, Orsolini P. New PEGs for peptisssde and protein modifcation, suitable for identifcation of the PEGylation site. Bioconj Chem 2001;12:62-70. (Pubitemid 32111455)
105. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY, Arnold S, Cheng PNM, Wheatley DN, Lo WH, Leung YC. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: Preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009;9:article 9.
106. Caliceti P, Schiavon O, Veronese FM, Chaiken IM. Efects of monomethoxypoly(ethylene glycol) modifcation of ribonuclease on antibody recognition, substrate specifcity and conformational stability. J Molec Recognit 1990, 3: 89-93.
107. Chiu H-C, Zapilsky S, Kopeckova P, Kopecek J. Enzymatic activity of chymotrypsin and its poly(ethylene glycol) conjugates towards low and high molecular weight substrates. Bioconj Chem 1993;4:290-295.
108. Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceut Res 1996;13:996-1002. (Pubitemid 26258997)
109. Freitas DdS, Abrahao-Neto J. Biochemical and biophysical characterization of lysozyme modifed by PEGylation. Int J Pharm 2010;392:111-117.
110. Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specifc PEGylation with preserved bioactivity. Int J Pharm 2000;198:83-95. (Pubitemid 30155552)
111. Fishburn CS. Te pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97:4167-4183.
112. Foser S, Weyer K, Huber W, Certa U. Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers. Pharmacogenom J 2003;3:312-319. (Pubitemid 38072169)
113. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitmuller T. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Express Purifcat 2003;30:78-87. (Pubitemid 36815235)
114. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima F, Chang S, Chu H, Mukku V, CanovaDavis E, Somer T, Cronin M, Winkler M, Wells JA. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biolog Chem 1996;271:21969-21977. (Pubitemid 26303822)
115. Sahu RK, Nacharaju P, Manjula BN, Acharya SA. Induced plasma expander-like properties as a function of PEG chains on extension arm facilitated PEGylation of albumin: 'mushroom to brush-like' conformational transition of the PEG-albumin conjugate. Artifc Cells, Blood Subst Biotechnol 2009;37:245-256.
116. Zhai YQ, Zhao YJ, Lei JD, Su ZG, Ma GH. Enhanced circulation half-life of site-specifc PEGylated rhG-CSF: Optimization of PEG molecular weight. J Biotechnol 2009;142:259-266.
117. Na DH, Youn YS, Lee IB, Park EJ, Park CJ, Lee KC. Efect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue. Pharm Dev Technol 2006;11:513-519. (Pubitemid 44852433)
118. Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Experim Hematol 1999;27:425-432. (Pubitemid 29125050)
119. Eliason JF, Greway A, Tare N, Inoue T, Bowen S, Dar M, Yamasaki M, Okabe M, Horii I. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells 2000;18:40-45. (Pubitemid 30064890)
120. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 2003;55:1279-1291. (Pubitemid 37464562)
121. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002;54:477-485. (Pubitemid 34615544)
122. Gaertner H F, Oford RE. Site-specifc attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconj Chem 1996;7:38-44.
123. Wetzel R, Halualani R, Stults JT, Quan CA General method for highly selective cross-linking of unprotected polypeptides via pH-controlled modifcation of N-terminal alpha-amino groups. Bioconj Chem 1990;1:114-122.
124. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Terapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnol 1999;17:780-783. (Pubitemid 29365106)
125. Wilchek M, Bayer EA. Labeling glycoconjugates with hydrazide reagents. Meth Enzymol 1987;138:429-442. (Pubitemid 17086714)
126. Wolfe CAC, Hage DS. Studies on the rate and control of antibody oxidation by periodate. Analyt Biochem 1995;231:123-130.
127. Krinner EM, Hepp J, Hofmann P, Bruckmaier S, Petersen L, Petsch S, Parr L, Schuster I, Mangold S, Lorenczewski G, Lutterbuse P, Buziol S, Hochheim I, Volkland J, Molhoj M, Sriskandarajah M, Strasser M, Itin C, Wolf A, Basu A, Yang K, Filpula D, Sorensen P, Kufer P, Baeuerle P, Raum T. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng Des Sel 2006;19:461-470. (Pubitemid 44408906)
128. Li XQ, Lei JD, Su ZG, Ma GH. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Process Biochem 2007;42:1625-1631.
129. Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005;11:6247-6255. (Pubitemid 41262955)
130. Matsushima A, Nishumura H, Ashihara Y, Yakata Y, Inada Y. Modifcation of E. coli asparaginase with 2,3-bis(O-methoxypolyethylene glycol)-6-chloro-s- triazine (activated PEG2); disappearance of binding ability towards anti-serum and retention of enzymatic activity. Chem Lett 1980:773-776.
131. Veronese FM, Caliceti P, Schiavon O. Branched and linear poly(ethylene glycol): Infuence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Compatib Polym 1997;12: 196-207. (Pubitemid 27470395)
132. Webster R, Xie R, Didier E, Finn R, Finnessy J, Edgington A, Walker D. PEGylation of somatotropin (recombinant human growth hormone): Impact on its clearance in humans. Xenobiotica 2008;38:1340-1351.
133. Seely JE, Richey CW. Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. J Chromatogr A 2001;908:235-241. (Pubitemid 32332934)
134. Lecolley F, Tao L, Mantovani G, Durkin I, Lautru S, Haddleton DM. A new approach to bioconjugates for proteins and peptides ('pegylation') utilising living radical polymerisation. Chem Commun 2004;2026-2027. (Pubitemid 39389495)
135. Mantovani G, Lecolley F, Tao L, Haddleton DM, Clerx J, Cornelissen J, Velonia K. Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper-mediated living radical polymerization: A suitable alternative to PEGylation chemistry. J Am Chem Soc 2005;127:2966-2973. (Pubitemid 40349875)
136. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, Greenberger LM, Horak LD. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a captothecin-11 refractory model. Clin Cancer Res 2008;14:1888-1896. (Pubitemid 351469476)
137. Mero A, Spolaore B, Veronese FM, Fontana A. Transglutaminase-mediated PEGylation of proteins: Direct identifcation of the sites of protein modifcation by mass spectrometry using a novel monodisperse PEG. Bioconj Chem 2009;20:384-389.
138. Berna M, Dalzoppo D, Pasut G, Manunta M, Izzo L, Jones AT, Duncan R, Veronese FM. Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: Synthesis, characterization and cellular uptake. Biomacromolecules 2006;7:146-153. (Pubitemid 43154489)
139. Knauf MJ, Bell DP, Hirtzer P, Luo Z P, Young JD, Katre NV. Relationship of efective molecular-size to systemic clearance in rats of recombinant interleukin-2 chemically modifed with water-soluble polymers. J Biolog Chem 1988;263:15064-15070.
140. Schafer C, Critchfeld F, Nair J. Te absorption and excretion of a liquid polyethylene glycol. J Am Pharmaceut Assoc: Sci Ed 1950;39:340-344.
141. Nieforth KA, Nadeau R, Patel IH. Use of an indirect pharmacodynamic stimulation model of MW protein induction to compare in vivo activity of interferon-a2a and a polyethylene glycol-modifed derivative in healthy subjects. Clin Pharmacol Terapeut 1996;59:636-646. (Pubitemid 26233419)
142. Hu T, Li D, Manjula BN, Acharya SA. Autoxidation of the site-specifcally PEGylated hemoglobins: Role of the PEG chains and the sites of PEGylation in the autoxidation. Biochemistry 2008;47:10981-10990.
143. Hooftman G, Herman S, Schacht E. Poly(ethylene glycol)s with reactive endgroups. 2. Practical consideration for the preparation of protein-PEG conjugates. J Bioact Compat Polym 1996;11:135-159. (Pubitemid 26193706)
144. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharmaceut Sci Technol Today 1998;1:352-356. (Pubitemid 28526964)
145. Berger H, Pizzo S V. Preparation of polyethylene-glycol tissue plasminogen-activator adducts that retain functional-activity-characteristics and behavior in 3 animal species. Blood 1988;71:1641-1647.
146. Busby TF, Ingham KC. Separation of macromolecules by ultrafltration- removal of poly(ethylene glycol) from human-albumin. J Biochem Biophys Meth 1980;2:191-206. (Pubitemid 10065900)
147. Hinds KD, Kim SW. Efects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002;54:505-530. (Pubitemid 34615546)
148. Kim TH, Lee H, Park TG. PEGylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 2002;23:2311-2317. (Pubitemid 34234832)
149. Nijs M, Azarkan M, Smolders N, Vincentelli J, Vries GMP, Duchateau J, Looze Y. Preliminary characterization of bovine beta-lactoglobulin after its conjugation to polyethylene glycol. Biotechnol Bioengineer 1997;54:40-49. (Pubitemid 27142531)
150. Baran ET, Ozer N, Hasirci V. Solid-phase enzyme modifctaion via afnity chromatography. J Chromatogr B 2003;794: 311-322. (Pubitemid 37101008)
151. Edwards CK, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Cosenza ME, Feige U, Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic infammatory diseases. Adv Drug Deliv Rev 2003;55:1315-1336. (Pubitemid 37464564)
152. Stoner MR, Fischer N, Nixon L, Buckel S, Benke M, Austin F, Randolph TW, Kendrick BS. Protein-solute interactions afect the outcome of ultrafltration/diafltration operations. J Pharm Sci 2004;93:2332-2342. (Pubitemid 39129630)
153. Hamidi M, Rafei P, Azadi A. Designing PEGylated therapeutic molecules: Advantages in ADMET properties. Expert Opin Drug Discov 2008;3:1293-1307.
154. Hoyle PC. Polymer-modifed proteins: Preclinical development and regulatory strategies. Adv Drug Deliv Rev 1991;6: 219-233.
155. Monkarsh SP, Spence C, Porter JE, Palleroni A, Nalin C, Rosen P, Bailon P. Isolation of positional isomers of mono-poly(ethylene glycol)ylated interferon-a2a and the determination of their biochemical and biological characteristics. ACS Sympos Series 1997;680:207-216. (Pubitemid 127444769)
156. Fee CJ. Size-exclusion reaction chromatography: A new technique for protein PEGylation. Biotechnol Bioengineer 2003;82: 200-206. (Pubitemid 36362920)
157. Snider J, Neville C, Yuan LC, Bullock J. Characterization of the heterogeneity of polyethylene glycol-modifed superoxide-dismutase by chromatographic and electrophoretic techniques. J Chromatography 1992;599:141-155.
158. McGof P, Baziotis AC, Maskiewicz R. Analysis of polyethylene-glycol modifed superoxide-dismutase by chromatographic, electrophoretic,
159. Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconj Chem 2004;15:1304-1313. (Pubitemid 39552020)
160. Kendrick BS, Kerwin BA, Chang BS, Philo JS. Online size-exclusion high-performance liquid chromatography light scattering and diferential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states. Analyt Biochem 2001;299:136-146. (Pubitemid 34053402)
161. Bedu-Addo F, Moreadith R, Advant SJ. Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design. AAPS Pharmsci 2002; 4:1-13.
162. Zhang M, Zhang Y, Zhu SY, Wu LF, Dou HZ, Yin CH. Synthesis and chromatographic separation of monomethoxypolyethylene glycol modifed insulin. Separat Sci Technol 2007;42:789-801. (Pubitemid 46447661)
163. Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-alpha 2b: A branched 40K polyethylene glycol derivative. Pharmaceut Res 2005;22:1374-1386. (Pubitemid 41176042)
164. Brumeanu T-D, Zaghouani H, Bona C. Purifcation of antigenized immunoglobulins derivatized with monomethoxylpolyethylene glycol. J Chromatogr A 1995;696:219-225.
165. Pabst TM, Buckley JJ, Hunter AK. Comparison of strong anion-exchangers for the purifcation of a PEGylated protein. J Chromatogr A 2007;1147:172-182. (Pubitemid 46466833)
166. Yun Q, Yang RE, Chen T, Bi JX, Ma GH, Su ZG. Reproducible preparation and efective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel 'PEG-pellet' PEGylation mode and ion-exchange chromatography. J Biotechnol 2005;118:67-74. (Pubitemid 40814535)
167. Poole CF. Te essence of chromatography. Amsterdam: Elsevier; 2003.
168. Cisneros-Ruiz M, Mayolo-Deloisa K, Przybycien TM, Rito-Palomares M. Separation of PEGylated from unmodifed ribonuclease A using sepharose media. Separat Purifcat Technol 2009;65:105-109.
169. Park EJ, Lee KC, Na DH. Separation of positional isomers of mono-poly(ethylene glycol)-modifed octreotides by reversed-phase high-performance liquid chromatography. J Chromatogr A 2009;1216:7793-7797.
170. Park EJ, Na DH. Optimization of octreotide PEGylation by monitoring with fast reversed-phase high-performance liquid chromatography. Analyt Biochem 2008;380:140-142.
171. Piedmonte DM, Treuheit MJ. Formulation of Neulasta (R) (pegflgrastim). Adv Drug Deliv Rev 2008;60:50-58.
172. Nie YJ, Zhang X, Wang XC, Chen JH. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Bioconj Chem 2006;17:995-999. (Pubitemid 44162618)
173. Schneiderheinze J, Walden Z, Dufeld R, Demarest C. Rapid online proteolytic mapping of pEGylated rhGH for identity confrmation, quantitation of methionine oxidation and quantitation of unPEGylated N-terminus using HPLC with UV detection. J Chromatogr B 2009;877:4065-4070.
174. Kudlicki W, Odom OW, Kramer G, Hardesty B. Activation and release of enzymatically inactive, full-length rhodanese that is bound to ribosomes as peptidyl-transfer-Rna. J Biolog Chem 1994;269:16549-16553. (Pubitemid 24200405)
175. Jones MN. Interaction of sodium dodecyl sulfate with polyethylene oxide. J Colloid Interface Sci 1967;23:36-42.
176. Odom OW, Kudlicki W, Kramer G, Hardesty B. An efect of polyethylene glycol 8000 on protein mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a method for eliminating this efect. Analyt Biochem 1997;245:249-252. (Pubitemid 27082260)
177. Kurfürst MM. Detection and molecular-weight determination of polyethylene glycol-modifed hirudin by staining after sodium dodecyl-sulfate polyacrylamide-gel electrophoresis. Analyt Biochem 1992;200:244-248.
178. Bailon P, Palleroni A, Schafer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconj Chem 2001;12:195-202. (Pubitemid 32235471)
179. Zheng CY, Ma GH, Su ZG. Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and rovides an alternative to HPLC in 2 characterization of protein PEGylation. Electrophoresis 2007;28:2801-2807. (Pubitemid 47323834)
180. Hardy E, Ramon J, Saez V, Baez R, Tejeda Y, Ruiz A. Detection of PEGylated proteins in polyacrylamide gels by reverse staining with zinc and imidazole salts. Electrophoresis 2008;29: 2363-2371. (Pubitemid 351866004)
181. Cunico RL, Gruhn V, Kresin L, Nitecki DE, Wiktorowicz JE. Characterization of polyethylene-glycol modifed proteins using charge-reversed capillary electrophoresis. J Chromatography 1991;559:467-477.
182. Bullock J, Chowdhury S, Johnston D. Characterization of poly(ethylene glycol)-modifed superoxide dismutase: Comparison of capillary electrophoresis and matrix-assisted laser desorption ionization mass spectrometry. Analyt Chem 1996;68:3258-3264.
183. Bullock J, Chowdhury S, Severdia A, Sweeney J, Johnston D, Pachla L. Comparison of results of various methods used to determine the extent of modifcation of methoxy polyethylene glycol 5000-modifed bovine cupri-zinc superoxide dismutase. Analyt Biochem 1997;254:254-262. (Pubitemid 28021089)
184. Li WJ, Su ZG. Quantitatively investigating monomethoxypolyethylene glycol modifcation of protein by capillary electrophoresis. J Biochem Biophys Meth 2004;59:65-74.
185. Na DH, Lee KC. Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-fight mass spectrometry. Analyt Biochem 2004;331:322-328. (Pubitemid 38953083)
186. Na DH, Park EJ, Jo YW, Lee KC. Capillary electrophoretic separation of high-molecular-weight poly(ethylene glycol)-modifed proteins. Analyt Biochem 2008;373:207-212.
187. Kraly J, Fazal MA, Schoenherr RM, Bonn R, Harwood MM, Turner E, Jones M, Dovichi NJ. Bioanalytical applications of capillary electrophoresis. Analyt Chem 2006;78:4097-4110. (Pubitemid 43927408)
188. Kostal V, Katzenmeyer J, Arriaga EA. Capillary electrophoresis in bioanalysis. Analyt Chem 2008;80:4533-4550. (Pubitemid 351842334)
189. Svergun DI, Ekstrom F, Vandegrif KD, Malavalli A, Baker DA, Nilsson C, Winslow RM. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: Implications for a new oxygen therapeutic. Biophys J 2008;94:173-181.
190. Lu YL, Harding SE, Turner A, Smith B, Athwal DS, Grossman JG, Davis KG, Rowe AJ. Efect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci 2008;97:2062-2079.
191. Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Muller F, Senn H. Structural and biophysical characterization of the 40 kDa PEG-interferon- alpha(2a) and its individual positional isomers. Bioconj Chem 2005;16:504-517. (Pubitemid 40696041)
192. Habeeb AFS. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Analyt Biochem 1966;14:328-336.
193. Treethammathurot B, Ovartlarnporn C, Wungsintaweekul J, Duncan R, Wiwattanapatapee R. Efect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin. Int J Pharm 2008;357:252-259. (Pubitemid 351614974)
194. Lopez-Cruz JI, Viniegra-Gonzalez G, Hernandez-Arana A. Termostability of native and pegylated Myceliophthora thermophila laccase in aqueous and mixed solvents. Bioconj Chem 2006;17:1093-1098. (Pubitemid 44162631)
195. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
196. Slavica A, Dib I, Nidetzky B. Selective modifcation of surface-exposed thiol groups in Trigonopsis variabilis (D)-Amino acid oxidase using poly(ethylene glycol) maleimide and its efect on activity and stability of the enzyme. Biotechnol Bioengineer 2007;96:9-17. (Pubitemid 46036156)
197. Huang YB, Komatsu T, Wang RM, Nakagawa A, Tsuchida E. Poly(ethylene glycol)-conjugated human serum albumin including iron porphyrins: Surface modifcation improves the O-2-transporting ability. Bioconj Chem 2006;17:393-398.
198. Wang YS, Youngster S, Bausch J, Zhang RM, McNemar C, Wyss D F. Identifcation of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000;39:10634-10640.
199. Heller MC, Carpenter JF, Randolph TW. Conformational stability of lyophilized PEGylated proteins in a phase-separating system. J Pharm Sci 1999;88:58-64. (Pubitemid 29037369)
200. Rodriguez-Martinez JA, Sola RJ, Castillo B, Cintron-Colon HR, Rivera-Rivera I, Barletta G, Griebenow K. Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnol Bioengineer 2008;101:1142-1149.
201. Mabrouk PA. Efect of pegylation on the structure and function of horse cytochrome c. Bioconj Chem 1994;5:236-241. (Pubitemid 2099538)
202. Tan HN, Yang SL, Feng Y, Liu CH, Cao JC, Mu GY, Wang FS. Characterization and secondary structure analysis of endostatin covalently modifed by polyethylene glycol and low molecular weight heparin. J Biochem 2008;144:207-213.
203. Hu T, Prabhakaran M, Acharya SA, Manjula BN. Infuence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem J 2005;392:555-564. (Pubitemid 43022735)
204. Basu A, Yang K, Wang ML, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu DC, Zhang ZF, Hua J, Hsieh MC, Zhou J, Petti G, Li XG, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconj Chem 2006;17:618-630. (Pubitemid 43794371)
205. Na DH, Lee KC, DeLuca PP. PEGylation of octreotide: II. Efect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharmaceut Res 2005;22:743-749. (Pubitemid 40768586)
206. Salmaso S, Bersani S, Scomparin A, Mastrotto F, Scherpfer R, Tonon G, Caliceti P. Tailored PEG for rh-G-CSF analogue site-specifc conjugation. Bioconj Chem 2009;20:1179-1185.
207. Cindric M, Cepo T, Galic N, Bukvic-Krajacic M, Tomczyk N, Vissers JPC, Bindila L, Peter-Katalinic J. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharmaceut Biomed Analysis 2007;44:388-395. (Pubitemid 46887640)
208. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R. Structural and biologic characterization of pegylated recombinant IFN-alpha 2b. J Interferon Cytokine Res 2001;21:1103-1115. (Pubitemid 34121056)
209. Wang Y-J, Liu Y-D, Chen J, Hao S-J, Hu T, Ma G-H, Su Z-G. Efcient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int J Pharm 2010;386:154-164.
210. Yu PZ, Qin D, Qin GH, Fan B, Ma GH, Su ZG. PEGylation of rhIL-1RA increased its solution stability at room temperature. Process Biochem 2009;44:1340-1345.
211. Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Experim Hematol 2006;34: 697-704. (Pubitemid 43737103)
212. Johnson C, Royal M, Moreadith R, Bedu-Addo F, Advant S, Wan M, Conn G. Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse-phase chromatography. Biomed Chromatogr 2003;17:335-344.
213. Carpenter J F, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharmaceut Res 1997;14:969-975. (Pubitemid 27371393)
214. Harris JM. Poly(ethylene glycol) chemistry: Biotechnical and biomedical applications. New York: Plenum Press; 1992.
215. Tattini V Jr, Parra DF, Polakiewicz B, Pitombo RNM. Efect of lyophilization on the structure and phase changes of PEGYlated-bovine serum albumin. Int J Pharm 2005;304: 124-134. (Pubitemid 41427656)
216. Cabrales P, Tsai AG, Winslow RM, Intaglietta M. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol 2005:289:H2392-2400. (Pubitemid 41698548)
217. Humphreys DP, Heywood SP, Henry A, Ait-Lhadj L, Antoniw P, Palframan R, Greenslade KJ, Carrington B, Reeks DG, Bowering LC, West S, Brandt HA. Alternative antibody Fab′ fragment PEGylation strategies: Combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007;20:227-234. (Pubitemid 351321304)
218. Roovers RC, van Dongen G, Henegouwen P. Nanobodies in therapeutic applications. Curr Opin Molec Terapeut 2007;9: 327-335. (Pubitemid 47255665)
219. Lee KC, Moon SC, Park MO, Lee JT, Na DH, Yoo SD, Lee HS, DeLuca P P. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharmaceut Res 1999;16:813-818. (Pubitemid 29284190)
220. Na DH, Park MO, Choi SY, Kim YS, Lee SS, Yoo SD, Lee HS, Lee KC. Identifcation of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry. J Chromatogr B-Analyt Technol Biomed Life Sci 2001;754:259-263. (Pubitemid 32241091)
221. Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC. Improved intestinal delivery of salmon calcitonin by Lys(18)-amine specifc PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efcacy. J Control Release 2006;114:334-342. (Pubitemid 44310815)
222. Tong Y, Zhong K, Tian H, Gao X, Xu X, Yin X, Yao W. Characterization of a monoPEG20000-Endostar. Int J Biolog Macromolec 2010;46:331-336.
223. Severs J, Samuels N, Teare J, Tollner A, Regan L. In: Characterization of PEGylated factor VIII molecules. American Society of Hematology Annual Meeting, 2006; Blood: 2006; p Abstract 4024.
224. Tang L, Pan C, Atwal H, Nixon J, Barnett T, Murphy JE, Mei B, Fournel M. In: PEGYlation of Factor VIII reduced the inhibitory efects of human antibody inhibitors on the Factor VIII molecule. American Society of Hematology Annual Meeting, 2006; Blood: 2006; p Abstract 4017.
225. Stigsnaes P, Frokjaer S, Bjerregaard S, van de Weert M, Kingshott P, Moeller EH. Characterisation and physical stability of PEGylated glucagon. Int J Pharm 2007;330:89-98. (Pubitemid 46099074)
226. Youn YS, Lee KC. Site-specifc PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12). Bioconj Chem 2007;18: 500-506. (Pubitemid 46493522)
227. Youn YS, Na DH, Yoo SD, Song SC, Lee KC. Chromatographic separation and mass spectrometric identifcation of positional isomers of polyethylene glycol-modifed growth hormone-releasing factor (1-29). J Chromatogr A 2004;1061:45-49. (Pubitemid 39576000)
228. Parkinson C, Scarlett JA, Trainer PJ. Pegvisomant in the treatment of acromegaly. Adv Drug Deliv Rev 2003;55:1303-1314. (Pubitemid 37474093)
229. Park EJ, Na DH, Lee KC. In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres. Int J Pharm 2007;343:281-283. (Pubitemid 47321029)
230. Suo X, Zheng C, Yu P, Lu X, Ma G, Su Z. Solid phase pegylation of hemoglobin. Artif Cells, Blood Subst Biotechnol 2009;37:147-155.
231. Lui FE, Kluger R. Enhancing nitrite reductase activity of modifed hemoglobin: Bis-tetramers and their PEGylated derivatives. Biochemistry 2009;48:11912-11919.
232. Diesen D, Stamler JS. S-nitrosylation and PEGylation of hemoglobin: Toward a blood substitute that recapitulates blood. J Molec Cellular Cardiol 2007;42:921-923. (Pubitemid 46695732)
233. Cabrales P, Kanika ND, Manjula BN, Tsai AG, Acharya SA, Intaglietta M. Microvascular PO2 during extreme hemodilution with hemoglobin site specifcally PEGylated at Cys-93(b) in hamster window chamber. Am J Physiol 2004;287: H1609-1617. (Pubitemid 39313265)
234. Yang K, Basu A, Wang M, Chintala R, Hsieh M-C, Liu S, Hua J, Zhang Z, Zhou J, Li M, Phyu H, Petti G, Mendez M, Janjua H, Peng P, Longley C, Borowski V, Mehlig M, Filpula D. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specifc PEGylation. Protein Engineer 2003;16:761-770. (Pubitemid 37442447)
235. Zhao J, Li XQ, Xiu ZL. Specifc-site PEGylation of hirudin on ion-exchange column and theoretical prediction and analysis of modifed sites by molecular dynamics simulation. Chem J Chin Univ-Chin 2009;30:1410-1416.
236. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN. A long-acting, highly potent interferon alpha-2 conjugate created using site-specifc PEGylation. Bioconj Chem 2005;16:200-207. (Pubitemid 40129694)
237. Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC. Long-acting interferon-alpha-2a modifed with a trimer-structured polyethylene glycol: Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm 2006;309: 87-93. (Pubitemid 43129469)
238. Reddy KR, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 kD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002;54:571-586. (Pubitemid 34615548)
239. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen DY, Hess DM, Chen LQ, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efcacy in a melanoma angiogenesis model. Bioconj Chem 2006;17:179-188. (Pubitemid 43157600)
240. Tsutsumi Y, Tsunoda S, Kamada H. PEGylation of interleukin-6 efectively increases its thrombopoietic potency. Trombosis Haemostasis 1997;77:168-173. (Pubitemid 27064988)
241. Huang Z, Ni CY, Chu YH, Wang SS, Yang SL, Wu XP, Wang XJ, Li XK, Feng WK, Lin SQ. Chemical modifcation of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity. J Biotechnol 2009;142:242-249.
242. Moreadith RW, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thromolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev 2003;55:1337-1345. (Pubitemid 37464565)
243. Tsutsumi Y, Kihira T, Tsunoda S. Molecular design of hybrid tumour necrosis factor alfa with polyethylene glycol increases its anti-tumour potency. Br J Cancer 1995;71:963-968.
244. Schiavon O, Caliceti P, Ferruti P, Veronese FM. Terapeutic proteins: A comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). Farmaco 2000;55: 264-269. (Pubitemid 30645491)
245. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68. (Pubitemid 350186186)